Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, WV, USA.
James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA.
Transl Behav Med. 2018 May 23;8(3):386-399. doi: 10.1093/tbm/ibx071.
Newly diagnosed diffuse large B-cell lymphoma (DLBCL) can pose significant challenges to care coordination. We utilized a social-ecological model to understand the impact of DLBCL diagnosis on visits to primary care providers (PCPs) and specialists, a key component of care coordination, over a 3-year period of cancer diagnosis and treatment. We used hurdle models and multivariable logistic regression with the Surveillance Epidemiology and End Result-Medicare linked dataset to analyze visits to PCPs and specialists by DLBCL patients (n = 5,455) compared with noncancer patients (n = 14,770). DLBCL patients were more likely to visit PCPs (adjusted odds ratio, AOR [95% confidence interval, CI]: 1.25 [1.18, 1.31]) and had greater number of visits to PCPs (β, SE: 0.384, -0.014) than noncancer patients. Further, DLBCL patients were more likely to have any visit to cardiologists (AOR [95% CI]: 1.40 [1.32, 1.47]), endocrinologists (1.43, [1.21, 1.70]), and pulmonologists (1.51 [1.36, 1.67]) than noncancer patients. Among DLBCL patients, the number of PCP visits markedly increased during the treatment period compared with the baseline period (β, SE: 0.491, -0.028) and then decreased to baseline levels (-0.464, -0.022). Visits to PCPs and specialists were much more frequent for DLBCL patients than noncancer patients, which drastically increased during the DLBCL treatment period for chronic care. More chronic conditions, treatment side effects, and frequent testing may have increased visits to PCPs and specialists. Interventions to improve care coordination may need to target the DLBCL treatment period, when patients are most vulnerable to poor care coordination.
新诊断的弥漫性大 B 细胞淋巴瘤 (DLBCL) 可能给医疗协调带来重大挑战。我们利用社会生态学模型来理解 DLBCL 诊断对初级保健提供者 (PCP) 和专科医生就诊的影响,这是医疗协调的关键组成部分,在癌症诊断和治疗的 3 年期间。我们使用障碍模型和多变量逻辑回归与监测、流行病学和最终结果-医疗保险链接数据集来分析 DLBCL 患者 (n = 5455) 与非癌症患者 (n = 14770) 相比,PCP 和专科医生的就诊情况。DLBCL 患者更有可能看 PCP (调整优势比 [95%置信区间,CI]:1.25 [1.18, 1.31]),并且看 PCP 的次数更多 (β,SE:0.384,-0.014) 比非癌症患者。此外,DLBCL 患者更有可能看心脏病专家 (AOR [95%CI]:1.40 [1.32, 1.47])、内分泌专家 (1.43 [1.21, 1.70]) 和肺病专家 (1.51 [1.36, 1.67]) 比非癌症患者。在 DLBCL 患者中,与基线期相比,治疗期间 PCP 的就诊次数明显增加 (β,SE:0.491,-0.028),然后降至基线水平 (-0.464,-0.022)。DLBCL 患者看 PCP 和专科医生的次数远远多于非癌症患者,在 DLBCL 治疗期间,慢性病的就诊次数急剧增加。更多的慢性疾病、治疗副作用和频繁的检查可能会增加 PCP 和专科医生的就诊次数。改善医疗协调的干预措施可能需要针对 DLBCL 治疗期间进行,因为此时患者最容易出现医疗协调不良的情况。